Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesEffects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
Annals of Rheumatic Diseases, 09/23/09
Dore RK et al. – This study extends evidence that denosumab increases BMD and reduces bone turnover in patients with RA and may provide a new therapeutic option for reducing systemic bone loss in patients with RA.
Methods- Subcutaneous placebo (n=75)
- Denosumab 60mg (n=71)
- Or denosumab 180mg (n=72) at baseline and 6 months
- Serum procollagen 1N terminal peptide (P1NP)
- Dual X-ray absorptiometry scans of the lumbar spine and hip
- Serum type I C-telopeptide (sCTx-I)
- Denosumab treatment increased mean lumbar spine and hip BMD
- Denosumab treatment reduced sCTx-I and P1NP versus placebo through 12 monthsli>
- Is regardless of baseline BMD or marker levels or concomitant bisphosphonate or glucocorticoid use
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of Buguzhi (Psoralea corylifolia fruit) extract on bone formation
Phytotherapy Research, 12/08/09
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer
Best Practice & Research: Clinical Rheumatology, 12/07/09
Osteoporosis risk assessment and ethnicity
Journal of General Internal Medicine, 12/07/09
Sponsor
Article Search
Sponsor